NCT03682289 2026-04-15
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
Phase 2 Recruiting
Clinical Trials
9 trialsNCT03907475 2026-04-13
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT02087423 2026-04-06
ATLANTIC
AstraZeneca
Phase 2 Completed
NCT02029001 2025-08-07
MOST plus
Centre Leon Berard
Phase 2 Recruiting
NCT05000710 2024-12-05
CORAL-Lung
Sheba Medical Center
Phase 2 Active not recruiting
NCT03439085 2024-07-09
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03691714 2023-12-08
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
University of Cincinnati
Phase 2 Active not recruiting
NCT03167619 2022-09-13
DORA
Duke University
Phase 2 Completed
NCT04184518 2020-06-02
CEDUVEAL-M
Grupo Español Multidisciplinar de Melanoma
Phase 2 Withdrawn